BibTex format
@article{Martin:2025:10.1016/j.lanmic.2025.101218,
author = {Martin, MA and Reynolds, SJ and Foley, BT and Nalugoda, F and Quinn, TC and Kemp, SA and Nakalanzi, M and Kankaka, EN and Kigozi, G and Ssekubugu, R and Gupta, RK and Abeler-Dörner, L and Kagaayi, J and Ratmann, O and Fraser, C and Galiwango, RM and Bonsall, D and Grabowski, MK and Chang, LW and Galiwango, RM and Grabowski, MK and Gray, RH and Jackson, JC and Kagaayi, J and Kankaka, EN and Kigozi, G and Laeyendecker, O and Quinn, TC and Reynolds, SJ and Santelli, J and Serwadda, D and Sewankambo, NK and Ssekasanvu, J and Ssekubugu, R and Ssempijja, V and Wawer, MJ and Nabukalu, D and Ndyanabo, A and Nakawooya, H and Nakukumba, J and Kigozi, GN and Nantume, BS and Resty, N and Kambasu, J and Nalugemwa, M and Nakabuye, R and Ssebanobe, L and Nankinga, J and Kayiira, A and Nanfuka, G and Ahimbisibwe, R and Tomusange, S and Kalibbali, S and Nakalanzi, M and Otobi, JO and Ankunda, D and Ssembatya, JL and Ssemanda, JB and Kairania, R and Kato, E and Kisakye, A and Batte, J and Ludigo, J and },
doi = {10.1016/j.lanmic.2025.101218},
journal = {The Lancet Microbe},
title = {HIV drug resistance during antiretroviral therapy scale-up in Uganda, 2012–19: a population-based, longitudinal study},
url = {http://dx.doi.org/10.1016/j.lanmic.2025.101218},
volume = {6},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BackgroundWith scale-up of antiretroviral therapy (ART) in sub-Saharan Africa, increasing pretreatment HIV drug resistance has been reported; however, the broader effect of ART expansion on population-level resistance patterns remains insufficiently quantified. We aimed to estimate the longitudinal prevalence of drug resistance and resistance-conferring mutations.MethodsThis study used data collected as part of the Rakai Community Cohort Study (RCCS), an open population-based census and cohort study conducted in southern Uganda. At each survey round, residents aged 15–49 years are invited to participate and receive a structured questionnaire that obtains sociodemographic, behavioural, and health information, including self-reported past and current ART use. Voluntary HIV testing is conducted using a rapid test algorithm and a venous blood sample. People with HIV provide samples for viral load quantification and deep sequencing. We analysed RCCS survey, HIV viral load, and deep sequencing (which was used to predict resistance) data from five survey rounds. The key outcomes were the population prevalence of viraemic people with HIV with non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor, or multiclass resistance among all participants (regardless of HIV serostatus) in the 2015 and 2017 surveys. Prevalence of class-specific resistance and resistance-conferring substitutions were estimated using robust log-Poisson regression.FindingsBetween Aug 10, 2011, and Nov 4, 2020, there were 43 361 participants in the RCCS and 7923 (18·27%) people with HIV. Over five survey rounds, 93 622 participant visits occurred, among which 17 460 (18·65%) were from people with HIV. Over the analysis period, the median age of study participants remained similar (28 years [22–35] in 2012 and 29 years [21–38] in 2019). Sufficient data were available to reliably genoty
AU - Martin,MA
AU - Reynolds,SJ
AU - Foley,BT
AU - Nalugoda,F
AU - Quinn,TC
AU - Kemp,SA
AU - Nakalanzi,M
AU - Kankaka,EN
AU - Kigozi,G
AU - Ssekubugu,R
AU - Gupta,RK
AU - Abeler-Dörner,L
AU - Kagaayi,J
AU - Ratmann,O
AU - Fraser,C
AU - Galiwango,RM
AU - Bonsall,D
AU - Grabowski,MK
AU - Chang,LW
AU - Galiwango,RM
AU - Grabowski,MK
AU - Gray,RH
AU - Jackson,JC
AU - Kagaayi,J
AU - Kankaka,EN
AU - Kigozi,G
AU - Laeyendecker,O
AU - Quinn,TC
AU - Reynolds,SJ
AU - Santelli,J
AU - Serwadda,D
AU - Sewankambo,NK
AU - Ssekasanvu,J
AU - Ssekubugu,R
AU - Ssempijja,V
AU - Wawer,MJ
AU - Nabukalu,D
AU - Ndyanabo,A
AU - Nakawooya,H
AU - Nakukumba,J
AU - Kigozi,GN
AU - Nantume,BS
AU - Resty,N
AU - Kambasu,J
AU - Nalugemwa,M
AU - Nakabuye,R
AU - Ssebanobe,L
AU - Nankinga,J
AU - Kayiira,A
AU - Nanfuka,G
AU - Ahimbisibwe,R
AU - Tomusange,S
AU - Kalibbali,S
AU - Nakalanzi,M
AU - Otobi,JO
AU - Ankunda,D
AU - Ssembatya,JL
AU - Ssemanda,JB
AU - Kairania,R
AU - Kato,E
AU - Kisakye,A
AU - Batte,J
AU - Ludigo,J
AU - Nampijja,A
AU - Watya,S
AU - Nehemia,K
AU - Anyokot,M
AU - Mwinike,J
AU - Kibumba,G
AU - Ssebowa,P
AU - Mondo,G
AU - Wasswa,F
AU - Nantongo,A
AU - Kakembo,R
AU - Galiwango,J
AU - Ssemango,G
AU - Redd,AD
AU - Kennedy,CE
AU - Wagman,J
AU - Kreniske,P
AU - Abeler-Dörner,L
AU - Ayles,H
AU - Bonsall,D
AU - Bowden,R
AU - Calvez,V
AU - Cohen,M
AU - Dennis,A
AU - de,Oliveira T
AU - Essex,M
AU - Fidler,S
AU - Frampton,D
AU - Fraser,C
AU - Grabowski,MK
AU - Golubchik,T
AU - Gupta,R
AU - Hayes,R
AU - Herbeck,J
AU - Hoppe,A
AU - Kagaayi,J
AU - Kaleebu,P
AU - Kellam,P
AU - Kityo,C
AU - Brown,AL
AU - Lingappa,J
AU - Moyo,S
AU - Novitsky,V
AU - Ndungu,T
AU - Paton,N
AU - Pillay,D
AU - Quinn,T
AU - Rambaut,A
AU - Ratmann,O
AU - Seeley,J
AU - Ssemwanga,D
AU - Tanser,F
AU - Wawer,M
DO - 10.1016/j.lanmic.2025.101218
PY - 2025///
SN - 2666-5247
TI - HIV drug resistance during antiretroviral therapy scale-up in Uganda, 2012–19: a population-based, longitudinal study
T2 - The Lancet Microbe
UR - http://dx.doi.org/10.1016/j.lanmic.2025.101218
UR - https://doi.org/10.1016/j.lanmic.2025.101218
VL - 6
ER -